Clinical Trial: SWOG S2302

SWOG S2302

Status: Open

Pragmatica – Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Eligible for screening study DCP 001

S2302 will be closed to accrual, effective December 20, 2024 at 12:00pm Pacific Time.